Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;29(8):2400089.
doi: 10.2807/1560-7917.ES.2024.29.8.2400089.

Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024

Marine Maurel  1 , Jennifer Howard  1 , Esther Kissling  1 , Francisco Pozo  2   3 , Gloria Pérez-Gimeno  4   2 , Silke Buda  5 , Noémie Sève  6 , Adele McKenna  7 , Adam Meijer  8 , Ana Paula Rodrigues  9 , Iván Martínez-Baz  10 , Ivan Mlinarić  11 , Neus Latorre-Margalef  12 , Gergő Túri  13 , Mihaela Lazăr  14 , Clara Mazagatos  4   2 , Aitziber Echeverria  10 , Stephen Abela  15 , Marc Bourgeois  16 , Ausenda Machado  9 , Ralf Dürrwald  17 , Goranka Petrović  11 , Beatrix Oroszi  13 , Ligita Jancoriene  18 , Alexandru Marin  19 , Petr Husa  20 , Roisin Duffy  7 , Frederika Dijkstra  8 , Virtudes Gallardo García  21 , Luise Goerlitz  5 , Vincent Enouf  22 , Charlene Bennett  23 , Mariëtte Hooiveld  24 , Raquel Guiomar  25 , Camino Trobajo-Sanmartín  10 , Vesna Višekruna Vučina  11 , Tove Samuelsson Hagey  12 , Ana Sofía Lameiras Azevedo  26 , Jesús Castilla  10 , Gerd Xuereb  27   15 , Bénédicte Delaere  16 , Verónica Gómez  9 , Kristin Tolksdorf  5 , Sabrina Bacci  28 , Nathalie Nicolay  28 , Marlena Kaczmarek  28 , Angela Mc Rose  1 ; European IVE group  29
Affiliations

Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024

Marine Maurel et al. Euro Surveill. 2024 Feb.

Abstract

Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.

Keywords: Europe; influenza; multicentre study; test-negative design; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Ligita Jancoriene has received honoraria fees for lectures from Pfizer, Viatris, Swixx Biopharma. All other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Sitesa participating in VEBIS European primary care and hospital influenza vaccine effectiveness studies, September 2023−January 2024 (n  =  15)
Figure 2
Figure 2
Number of influenza cases and test-negative controls by week of onset, VEBIS European (A) primary care and (B) hospital studies, September 2023–January 2024 (n = 17,016a)
See this image and copyright information in PMC

References

    1. European Centre for Disease Prevention and Control (ECDC). European Respiratory Virus Surveillance Summary (ERVISS), 2024, Week 05. Stockholm: ECDC. [Accessed: 16 Feb 2024]. Available from: https://erviss.org
    1. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season. Geneva: WHO; 2023. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influ...
    1. European Centre for Disease Prevention and Control (ECDC). Vaccine Scheduler. Stockholm: ECDC. [Accessed: 31 Jan 2024]. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDise...
    1. European Centre for Disease Prevention and Control (ECDC). Core protocol for ECDC studies of vaccine effectiveness against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection at primary care level: version 1.0, September 2023. Stockholm: ECDC; 2023. Available from: https://data.europa.eu/doi/10.2900/25966 - DOI
    1. European Centre for Disease Prevention and Control (ECDC). Core protocol for ECDC VEBIS studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or seasonal influenza - Version 2.0. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-vaccin...

Substances

LinkOut - more resources